Menopause. Menopausal and female climacteric states , Other specified menopausal and perimenopausal disorders
Conditions
Interventions
Intervention 1: topical ointment containing Hops nanoparticles on
skin of arm, per day, during 12 weeks. Intervention 2: topical ointment containing placebo on skin of arm, per day, during 12 weeks.
Treatment - Drugs
Placebo
topical ointment containing Hops nanoparticles on
skin of arm, per day, during 12 weeks
topical ointment containing placebo on skin of arm, per day, during 12 weeks
Sponsors
Vice-Chancellor in Research Affairs Research Institute for Endocrine Sciences, Shahid Beheshti Unive
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: • last menstrual period between 12 months and 2 years before the beginning of the study ; • age between 45 and 60 years; • not using of any hormone replacement therapies in the past 6 months; • Not having any allergic disorders to phytoestrogens; • not having abnormal uterine bleeding, breast cancer and uterine cancer; • not having a past history of breast cancer, endometrial cancer, thromboembolism disorders and coronary heart disease; • not having any chronic dermatologic disorders. Exclusion criteria: Patients presenting with systematic illness, allergic reactions ,and use of any interfering drugs were excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early Menopausal Symptoms. Timepoint: before-after. Method of measurement: Menopausal Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stradiol level. Timepoint: before-after. Method of measurement: biochemical tests.;Cytokine profile. Timepoint: before-after. Method of measurement: inflammatory index analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Abdi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed